Thus, treatment of head and neck squamous cell carcinoma and non-small cell lung cancer cells with the fully humanized anti-IGF-IR monoclonal antibody (MAb), Cixutumumab, induced Akt and mammalian target of rapamycin (mTOR) activation, resulting in EGFR, Akt1, and survivin synthesis and EGFR pathway activation. The gene discussed is AKT1; the disease is non-small cell lung carcinoma.